NOT FOR DISTRIBUTION OR
RELEASE, DIRECTLY OR INDIRECTLY, TO THE U.S NEWS WIRE SERVICES OR
FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN,
OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.
Reference is made to the
stock exchange notice released earlier today by Hofseth BioCare ASA
("HBC" or "Company") regarding a private placement of NOK 23.6
million through issuance of 11,800,000 new shares (the "Private
Placement"). The subscription price in the Private Placement was
NOK 2 per share.
In the Private Placement,
the following subscribers surpassed a threshold for disclosure of
large shareholdings:
- Bonafide Global Fish
Fund subscribed 2,000,000 new shares and thus increased their total
shareholding in the Company to 5.64 %. Following the Private
Placement, Bonafide Global Fish Fund owns 6,892,203 shares in the
Company.
- Hofseth AS subscribed
5,302,571 new shares and thus increased their total shareholding in
the Company to 10.4 %. Following the Private Placement, Hofseth AS
owns 12,713,514 shares in the Company.
- Hofseth International
AS subscribed 1,750,000 new shares and thus increased their total
shareholding in the Company to 3,46 %. Following the Private
Placement, Hofseth International AS owns 6.87 % in the Company
including related companies, Hofseth Logistics AS and Seafood
Farmers of Norway AS. Hofseth International AS (and associated
companies) holds a total shareholding of 8,397,881 shares in the
Company.
- As a consequence of
the Private Placement, the shareholding of Jan Petterson (and
associated companies) in the Company has decreased to 9.2%.
Following the Private Placement, Jan Pettersson (and associated
companies) still own 11,245,651 shares in the Company.
For more information, please
contact:
Jon Olav Ødegård, CEO Hofseth BioCare ASA
Mobile: +47 936 32 966
Email: joo@hofsethbiocare.no
About Hofseth BioCare
ASA:
HBC is a Norwegian biotech company that offers high-value
ingredients and finished products for humans and pets. The company
is founded on the core values of sustainability, traceability and
optimal utilization of natural resources. Through an innovative
hydrolysis technology, HBC is able to preserve the quality of
salmon oil, proteins and calcium, prepared of fresh salmon
off-cuts. HBC's objective is to contribute to the efficient use of
marine resources and deliver quality products for ingredients and
finished consumer products in the nutrition market.
This information is subject
to the disclosure requirements pursuant to section 5-12 of the
Norwegian Securities Trading Act.